Many of us may have taken ibuprofen, sometimes two pills at once, especially when we are struggling with menstrual cramps. Well, as good these pills may be in treating the pain, they are not recommended for your health, especially if you are someone who consumes it on a daily basis or frequently. Gastroenterologist Trisha Pasricha, MD, writes in The Washington Post about why should you avoid taking nonsteroidal anti-inflammatory drugs, or NSAIDs, such as ibuprofen, naproxen and aspirin.

What happens when you consume pain killers?

She writes that NSAIDs are great in treating short term pain. They comprise of a group of drugs that inhibit the production of prostaglandins, which serve as a variety of purposes in the body. Some of which also includes contracting the uterus during menses and regulating blood flow in our vessels.

While one to two doses every now and then is okay, following a regular dosage routine, which could range from several times a month, or twice in an hour or so could lead to health risk. NSAIDs are well known to increase intestinal permeability. This means, these painkillers could damage the lining of your gut.

A 2018 review by Ingvar Bjarnason et. al., also writes about how NSAIDs can reduce the blood flow in the tiny vessels that feeds our guts. It can also disrupt the intestinal cells forming a barrier between the outside world and your insides.

What can be done?

While people with conditions like migraines, chronic back pain or bad period cramps can find NSAIDs to be helpful. It is always advisable to have a chat with your physicians to explore NSAID alternatives.

Pasricha suggests acetaminophen.

However, if someone is in dire need of NSAID, her tip is to take the pill right at the start of your symptoms. She says that the drug can do a far better job at stopping things at the source than chasing after all prostaglandins.

Why is it a concern?

NSAIDs are available as over the counter drug, which means people do not need a prescription for it and can make medical decision about them without the guidance of a physician.

A 2018 study published in the Official Journal of the International Society for Pharmacoepidemiology by David W Kaufman, et.al., found that 15% of adult ibuprofen users in the US have exceeded the maximum recommended daily dose. The study also mentions that more than a third of ibuprofen users were taking other NSAIDs, like aspirin and naproxen, while consuming ibuprofen at the same time. Out of these, 61% did not realise that they were using NSAIDs.

Pasricha talks about how it ruptures the gut wall, as she herself has rushed to the hospital in the middle of the night "far more times than" she can count "to perform an emergency endoscopy on someone who was bleeding profusely from an ulcer caused by NSAID".

Another 2009 study published in the American Journal of Gastroenterology states that as many as 1 in 4 chronic NSAID users will get an ulcer and about 4% will bleed or rupture through the gut wall.

An older study from 2005 titled A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy, found that as 75 percent of people regularly using NSAIDs develop low-grade inflammation in their small bowels. NSAIDs can also lead to development of fatty liver disease. This happens because your gut lining becomes more permeable, more toxins and bacteria from the outside world enters your liver and leads to inflammation.

A 2011 study titled Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials, states that as many as 6% of people taking NSAIDs regularly have found their blood count dropping within a few months of starting the medicines, this suggests that this is due to the small, slow amount of bleeding in the gut overtime.

British pop star Jessie J has shared an update on her recovery after undergoing a second breast reconstruction surgery.

The 38-year-old singer-songwriter took to Instagram to share a series of photos, including one taken after her latest surgery. In the picture, she is seen wearing a hospital gown and giving a thumbs-up, with the caption, “to healing.”

The post marks Jessie’s first update since September, when she announced she would be taking a break from social media ahead of her surgery.

Jessie was diagnosed with early-stage breast cancer in 2025 and underwent a mastectomy. She announced in May 2026 that she was cancer-free.

Sharing the emotional news on Instagram, she admitted she "sobbed for hours and then exhaled for the first time in a year."

Jessie J’s Breast Cancer Diagnosis

Also read: World Breast Cancer Day 2026: Life After Breast Cancer, The Fear No One Sees

Jessie announced her diagnosis in June 2025, shortly after performing at Capital’s Summertime Ball at London’s Wembley Stadium. She spoke candidly about her diagnosis and the surgery she would undergo.

In a video message, she shared that she had been “in and out of tests” before receiving a diagnosis of early breast cancer.

“Cancer sucks in any form,” she said, adding that she was holding on to the word “early.”

Using her characteristic dark humor, she described the surgery as “a very dramatic way to get a boob job” and told her followers, “I will come back with massive boobs and more music.”

However, she also spoke openly about the emotional toll of the diagnosis, saying, “I need to process it and talk about it” and “I need a hug.”

What Is Breast Reconstruction Surgery?

Breast reconstruction surgery aims to restore the shape and contour of the breast after a mastectomy, which involves removing the entire breast. Depending on the cancer and the treatment plan, nearby skin and lymph nodes may also be removed.

Following a mastectomy, patients may choose breast reconstruction to restore breast shape and symmetry. The procedure can be performed at the same time as the mastectomy or at a later date, depending on the patient's circumstances and treatment plan.

Read More: Experts Explain Most Overlooked Breast Changes That Can Delay Diagnosis In Men

Why Do Some Patients Need Multiple Breast Reconstruction Surgeries?

According to the American Cancer Society, breast reconstruction often involves more than one operation. The number and type of procedures depend on the reconstruction method, the patient's needs and the desired outcome.

There are two main types of breast reconstruction:

• Implant reconstruction: A saline or silicone implant is used to rebuild the breast.
• Tissue flap reconstruction: Tissue taken from another part of the body is used to reconstruct the breast.

In some cases, surgeons combine the two approaches.

Reconstruction may be immediate, taking place during breast cancer surgery, or delayed until a later date. Both implant-based and tissue flap reconstruction can be performed using either approach.

After the initial reconstruction, some patients may undergo additional procedures to refine the breast's appearance or feel. These may include fat grafting, scar revision or procedures to recreate the nipple and areola, sometimes using medical tattooing.

Benefits And Risks Of Breast Reconstruction

Breast reconstruction can help restore breast shape and symmetry after a mastectomy. For some patients, it may also improve body image, confidence and emotional well-being. However, the benefits vary from person to person.

As with other surgical procedures, breast reconstruction carries potential risks and complications, including:

• Infection
• Fluid or blood accumulation
• Delayed wound healing
• Changes in sensation
• Implant-related complications
• Capsular contracture
• Blood clots, including deep vein thrombosis and pulmonary embolism
• Psychological effects.

Low-dose naltrexone has received plenty of attention as a strong candidate for treating people with chronic fatigue after COVID-19. But a new randomised clinical trial has found no significant improvement in fatigue, pain or any other symptoms when compared to a placebo.

The study, posted on medRxiv, examined low-dose naltrexone (LDN) in adults with post-COVID fatigue syndrome. The findings challenge hopes that an existing repurposed drug could provide relief for people whose symptoms have not subsided months after infection.

The paper has not yet undergone peer review, which means its findings have not been independently evaluated in a formal manner.

Study Based On 160 Adults With Long COVID

Also read: 'It’s The Best-Studied Vaccine In Human History': Former CDC Adviser Busts Common Myths About COVID Vaccines

160 adults aged 19 to 69 from British Columbia and Ontario, Canada participated in the trial. Participants had developed symptoms that resembled myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) after a SARS-CoV-2 infection.

Researchers randomly assigned participants either low-dose naltrexone or a placebo for 16 weeks. The naltrexone dose began at 1 milligram daily and increased to a maximum of 4.5 milligrams, depending on how participants tolerated the treatment.

The main outcome was fatigue severity, which was measured using the Fatigue Severity Scale. At the end of the study, the average fatigue score was 4.2 in the LDN group and 4.4 in the placebo group.

The difference between the groups was not statistically significant, meaning the trial proved that the drug did not improve fatigue.

Researchers also found no significant differences between the groups in pain, overall ME/CFS symptoms, daily step counts or any other health aspects related to quality of life.

These results suggest that LDN did not provide any measurable benefit for the participants. The study also found that LDN was generally well tolerated over the 16-week period.

However, adverse events classified as grade 3 or higher were reported in five participants in the LDN group, or 6.2%, compared with three participants in the placebo group or 3.8%.

Why Has Low-Dose Naltrexone Attracted Interest?

Also read: 'I Never Recovered From That Crash': US Physicist Recalls Her Years-Long Battle With Long COVID

Naltrexone is an established medicine used at standard doses to treat alcohol use disorder and opioid use disorder. At much lower doses, it has been tested for conditions involving chronic pain, inflammation and fatigue.

LDN’s effects on immune signalling and inflammatory conditions have sparked interest in its potential use for long COVID, a condition that can involve fatigue, cognitive difficulties, pain, breathlessness and symptoms affecting several biological functions.

Researchers Caution

The findings apply specifically to adults with post-COVID fatigue syndrome who met the study’s criteria for ME/CFS-like symptoms.

Long COVID refers to symptoms that occur after a SARS-CoV-2 infection and cannot be explained by another diagnosis. Symptoms vary widely and may include fatigue, cognitive difficulties, breathlessness, sleep disturbances and problems with everyday activities.

Some people improve over time, while others experience prolonged illness that affects their ability to lead routine lives.

The results do not mean that long COVID symptoms are untreatable. Instead, they highlight how difficult it can be to identify effective treatments for a condition with varied symptoms.

There are currently no FDA-approved medicines specifically for long COVID, and care often focuses on managing individual symptoms.

People taking or considering naltrexone should discuss its benefits and risks with a healthcare professional rather than starting or changing treatment on their own.

Low-dose aspirin could play a key role in lowering the risk of dementia significantly in some older adults, according to a new genetic analysis. However, the benefit does not come without a complication: major bleeding.

The study, led by researchers at Monash University in Australia, is based on data from more than 13,500 participants in the ASPREE trial, which investigated the effects of low-dose aspirin in older adults. The study was published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.

Researchers found that the benefit was mostly seen among people with a specific genetic trait linked with platelet count.

70% Lower Dementia Risk Was Seen Among Older Adults

Also read: Aspirin & Colon Cancer: Lancet Study Explains Why It Could Help At An Earlier Stage But Not After Spread

Platelets are small blood components that help form clots and stop bleeding. Researchers have previously examined how aggregation of platelets might contribute to dementia, but the role of genetically influenced platelet counts still remains unclear.

The researchers examined genetic scores related to platelet count and compared dementia results among participants who were either assigned aspirin or placebo.

Among people in the highest 20% of platelet count genetic scores, dementia developed in 1% of those taking aspirin, compared with 3.3% of those receiving a placebo. This represented approximately a 70% lower risk.

Lead author Dr Peter Fransquet, a research fellow at Monash University's School of Public Health and Preventive Medicine, said, “Previous trials found aspirin didn't prevent dementia when everyone was considered together.”

“Our findings suggest there may be more to the story,” he said.

Risk Of Bleeding Increased

Also read: Trump Says He ‘Psychologically’ Needs To Pop Aspirin Every Day: But Is It Actually Safe?

The benefit was accompanied by a safety concern. Among participants in the same genetic subgroup, major bleeding occurred in 4.4% of those assigned to aspirin, compared to 2.1% of those given a placebo. That is a difference of 2.3 percentage points in both dementia cases and major bleeding events. In other words, the lower dementia rate cannot be considered in isolation from the increased bleeding risk.

Aspirin reduces the ability of platelets to form clots. This can be useful for certain people who need to take precaution against cardiovascular events, but it can also increase the risk of serious bleeding, including bleeding in the gastrointestinal tract or brain.

The study therefore does not prove that aspirin offers a favourable overall balance of benefits and harms for people with this genetic profile.

Could This Help Personalise Dementia Prevention?

The researchers found that the genetic signal was not linked to established genetic risk factors for Alzheimer's disease and dementia. Instead, it pointed towards platelet factor as a possible direction for further research.

“What's particularly interesting is that the signal wasn't linked to the established genetic risk factors for Alzheimer's disease and dementia,” Fransquet said. “Instead, it's pointing us towards platelet biology and gives us a new avenue to investigate.”

The findings could contribute to more personalised approaches to dementia prevention, in which treatments are tailored to characteristics that influence how individuals respond. But the results need to be replicated in other populations and tested in a clinical trial specifically designed for people with the identified genetic profile.

Fransquet said, “People shouldn’t start taking aspirin to prevent dementia on the basis of this study without consulting with their doctor, particularly given the increased risk of serious bleeding,” he said.